Literature DB >> 8937470

Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells.

K L Duncan1, M D Duncan, M C Alley, E A Sausville.   

Abstract

Cucurbitacin E has been identified by an empiric screening strategy as a sterol with potent growth inhibitory activity in vitro directed against prostate carcinoma explants (IC50 of 7-50 nM in 2- to 6-day exposures). The mechanism of cucurbitacin cytoxicity has not been elucidated previously. In the present study, we observed that cucurbitacin E caused marked disruption of the actin cytoskeleton, and in a series of cucurbitacin analogues, anti-proliferative activity correlated directly with the disruption of the F-actin cytoskeleton. The distribution of vimentin was also altered in cells exposed to cucurbitacin E, as vimentin associated with drug-induced membrane blebs. The appearance of microtubules was unaffected. Western blot analysis of intracellular actin in cells exposed to cucurbitacins and quantitation of rhodamine-phalloidin binding support the hypothesis that cucurbitacin treatment leads to an inappropriate increase in the filamentous or polymerized actin fraction in prostate carcinoma cells. We conclude that cucurbitacins are potent disruptors of cytoskeletal integrity. Prostate carcinoma cells appear notably sensitive to growth inhibition by cucurbitacin E.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8937470     DOI: 10.1016/s0006-2952(96)00557-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  28 in total

1.  The natural product cucurbitacin E inhibits depolymerization of actin filaments.

Authors:  Pia M Sörensen; Roxana E Iacob; Marco Fritzsche; John R Engen; William M Brieher; Guillaume Charras; Ulrike S Eggert
Journal:  ACS Chem Biol       Date:  2012-07-09       Impact factor: 5.100

2.  Cucurbitacin E induces apoptosis of human prostate cancer cells via cofilin-1 and mTORC1.

Authors:  Xiaolong He; Qi Gao; Yayong Qiang; Wei Guo; Yadong Ma
Journal:  Oncol Lett       Date:  2017-04-24       Impact factor: 2.967

3.  Growth inhibitory effect of Cucurbitacin E on breast cancer cells.

Authors:  Tian Lan; Linling Wang; Qian Xu; Weiguo Liu; Hongchuan Jin; Weimin Mao; Xian Wang; Xiaojia Wang
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

4.  Actin-aggregating cucurbitacins from Physocarpus capitatus.

Authors:  Katherine N Maloney; Masaki Fujita; Ulrike S Eggert; Frank C Schroeder; Christine M Field; Timothy J Mitchison; Jon Clardy
Journal:  J Nat Prod       Date:  2008-10-29       Impact factor: 4.050

5.  Cucurbitacins - a promising target for cancer therapy.

Authors:  Abdullah A Alghasham
Journal:  Int J Health Sci (Qassim)       Date:  2013-01

6.  Cucurbitacin E exhibits anti-inflammatory effect in RAW 264.7 cells via suppression of NF-κB nuclear translocation.

Authors:  Jing Qiao; Li-hui Xu; Jian He; Dong-yun Ouyang; Xian-hui He
Journal:  Inflamm Res       Date:  2013-01-30       Impact factor: 4.575

7.  Direct interaction of Cucurbitacin E isolated from Alsomitra macrocarpa to actin filament.

Authors:  Keiko Momma; Yuko Masuzawa; Naomi Nakai; Moeko Chujo; Akira Murakami; Noriyuki Kioka; Yasunori Kiyama; Toru Akita; Masaya Nagao
Journal:  Cytotechnology       Date:  2007-11-07       Impact factor: 2.058

Review 8.  Targeting karyotypic complexity and chromosomal instability of cancer cells.

Authors:  Anna V Roschke; Ilan R Kirsch
Journal:  Curr Drug Targets       Date:  2010-10       Impact factor: 3.465

9.  Cucurbitacin I inhibits cell motility by indirectly interfering with actin dynamics.

Authors:  David A Knecht; Rebecca A LaFleur; Alem W Kahsai; Christian E Argueta; Anwar B Beshir; Gabriel Fenteany
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

10.  The effectiveness of cucurbitacin B in BRCA1 defective breast cancer cells.

Authors:  Moltira Promkan; Sumana Dakeng; Subhas Chakrabarty; Oliver Bögler; Pimpicha Patmasiriwat
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.